Key facts
- Notable investors include US National Science Foundation, United States Department of Agriculture, Ag Ventures Alliance, Beta.MN, Minnesota Cup — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NovoClade
- ·The full record, as it builds
Funding rounds
No funding rounds for NovoClade are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NovoClade
Operator of a synthetic biology company intended to develop genetic bio-control for insect control. The company specializes in controlling mosquito populations and their role in spreading diseases by offering pest control that uses gene-editing technology, creating a line of sterile mosquitoes without harming the environment, enabling clients to develop formulas that limit the number of insects around to transmit diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Saint Paul, MN, United States
- Founded
- 2016
- Employees
- 9
- Website
- novoclade.com/
- Ownership
- Privately Held (backing)
NovoClade doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NovoClade shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NovoClade in its N-PORT filings yet. We sweep new filings monthly.